12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Company News  |  Other News

AstraZeneca neurology news

AstraZeneca filed suit in the U.S. District Court for the District of Columbia seeking to delay FDA approval of generic versions of psychiatric drugs Seroquel quetiapine and Seroquel XR by almost nine months. The suit follows news earlier this month that FDA denied a Citizen Petition from...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >